![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
Mixed vaccination with ChAdOx1-S followed by BNT162b2 induces a robust humoral immune response [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Tag: ChAdOx1 vaccine
Vaccine-induced immune thrombotic thrombocytopenia may worsen the severity of cerebral venous thrombosis
1. The primary outcome of mortality or dependency was greater in patients with VITT-associated CVT compared to non-VITT CVT (p=0.0061). ...
Third dose of ChAdOx1 nCoV-19 vaccine and prolonged second dose-intervals are both associated with increased antibody titers
1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody ...
Heterologous ChAdOx1 prime-boosted vaccination schedules are non-inferior to homologous vaccination
1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of ...
Mixed vaccination with ChAdOx1-S followed by BNT162b2 induces a robust humoral immune response
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 ...
Single dose mass vaccination against COVID-19 is linked with reductions in hospital admissions
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one ...
#VisualAbstract: ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there ...
ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, ...